Cargando…
Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer
BACKGROUND: Expression of transglutaminase 2 (TGase 2) is related to invasion and resistance to chemotherapeutic agents in several cancer cells. However, there has been only limited clinical validation of TGase 2 as an independent prognostic marker in cancer. METHODS: The significance of TGase 2 exp...
Autores principales: | Choi, Chang-Min, Jang, Se-Jin, Park, Seong-Yeol, Choi, Yong-Bock, Jeong, Jae-Heon, Kim, Dae-Seok, Kim, Hyun-Kyoung, Park, Kang-Seo, Nam, Byung-Ho, Kim, Hyeong-Ryul, Kim, Soo-Youl, Hong, Kyeong-Man |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196741/ https://www.ncbi.nlm.nih.gov/pubmed/21943122 http://dx.doi.org/10.1186/1476-4598-10-119 |
Ejemplares similares
-
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
por: Yu, Jeong Il, et al.
Publicado: (2020) -
A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor
por: Sohn, Joonhong, et al.
Publicado: (2010) -
Prognostic Significance of CHIP and RIPK3 in Non-Small Cell Lung Cancer
por: Kim, Jisup, et al.
Publicado: (2020) -
Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Jeong, Jae-Heon, et al.
Publicado: (2013) -
New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds
por: Kim, Soo-Youl
Publicado: (2018)